MX2013001470A - Formulaciones para infusion de lantibioticos de tipo b - Google Patents
Formulaciones para infusion de lantibioticos de tipo bInfo
- Publication number
- MX2013001470A MX2013001470A MX2013001470A MX2013001470A MX2013001470A MX 2013001470 A MX2013001470 A MX 2013001470A MX 2013001470 A MX2013001470 A MX 2013001470A MX 2013001470 A MX2013001470 A MX 2013001470A MX 2013001470 A MX2013001470 A MX 2013001470A
- Authority
- MX
- Mexico
- Prior art keywords
- infusion
- type
- lantibiotics
- formulations
- lantibiotic
- Prior art date
Links
- 108010062877 Bacteriocins Proteins 0.000 title abstract 3
- 238000001802 infusion Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000013020 final formulation Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1013513.5A GB201013513D0 (en) | 2010-08-11 | 2010-08-11 | Formulations |
| PCT/GB2011/001191 WO2012020219A2 (en) | 2010-08-11 | 2011-08-09 | Formulations for infusion of type b lantibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013001470A true MX2013001470A (es) | 2013-05-14 |
Family
ID=42931511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001470A MX2013001470A (es) | 2010-08-11 | 2011-08-09 | Formulaciones para infusion de lantibioticos de tipo b |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9192569B2 (enExample) |
| EP (1) | EP2603204A2 (enExample) |
| JP (1) | JP5865374B2 (enExample) |
| CN (1) | CN103108628B (enExample) |
| CA (1) | CA2807206A1 (enExample) |
| EA (1) | EA024344B1 (enExample) |
| GB (1) | GB201013513D0 (enExample) |
| MX (1) | MX2013001470A (enExample) |
| WO (1) | WO2012020219A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| CN109620979B (zh) * | 2018-12-29 | 2020-09-01 | 福建师范大学 | 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013513A (en) | 1963-03-25 | 1965-12-15 | Watney Combe Reid & Co Ltd | Improvements in and relating to hopping beer |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| GB8507528D0 (en) | 1985-03-22 | 1985-05-01 | Lepetit Spa | Basis monocarboxyamide derivatives |
| US5304540A (en) | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
| IN167138B (enExample) | 1988-08-17 | 1990-09-01 | Hoechst India | |
| GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IT1260505B (it) | 1992-06-01 | 1996-04-09 | Poli Ind Chimica Spa | Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon |
| IL107887A (en) | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
| US5512269A (en) * | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
| ATE255165T1 (de) | 1994-09-12 | 2003-12-15 | Aventis Pharma Gmbh | Rekombinantes mersacidin und verfahren zu seiner herstellung |
| US5866539A (en) | 1995-06-23 | 1999-02-02 | Ambi Inc. | Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US5985823A (en) | 1997-06-09 | 1999-11-16 | Ambi Inc. | Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon |
| US5958873A (en) | 1997-06-09 | 1999-09-28 | University Of Cincinnati | Oral formulation for treatment of bacteria-induced diseases of the colon |
| DE19745583A1 (de) | 1997-10-15 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben |
| US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| CA2413702A1 (en) | 2000-06-28 | 2002-01-03 | Teva Pharmaceuticals Industries Ltd. | Carvedilol |
| GB0110432D0 (en) | 2001-04-27 | 2001-06-20 | Plant Bioscience Ltd | Lantibiotic production |
| WO2002103010A1 (en) | 2001-06-14 | 2002-12-27 | Plant Bioscience Limited | Methods and materials for targeted gene disruption in actinomycete bacteria |
| US6861236B2 (en) | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| EP1558746A4 (en) | 2002-10-10 | 2006-11-22 | Molichem Medicines Inc | DURAMYCIN-CODING NUCLEIC ACIDS |
| MXPA05004121A (es) * | 2002-10-18 | 2006-02-17 | Molichem Medicines Inc | Metodos para tratar la enfermedad de ojo reseco con lantibioticos. |
| ATE356143T1 (de) | 2003-07-18 | 2007-03-15 | Vicuron Pharm Inc | Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon |
| US7351687B2 (en) | 2003-07-18 | 2008-04-01 | Vicuron Pharmaceuticals, Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
| JP2007523092A (ja) | 2004-02-17 | 2007-08-16 | キャンサーバックス コーポレイション | 新脈管形成阻害のための方法および組成物 |
| GB0406870D0 (en) | 2004-03-26 | 2004-04-28 | Novacta Biosystems Ltd | Improvements relating to the production of lantibiotics |
| EP1928900A1 (en) | 2005-09-27 | 2008-06-11 | Novacta Biosystems Limited | Variants of the lantibiotic mersacidin and their use |
| GB0600928D0 (en) | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
| CA2667167C (en) | 2006-10-27 | 2014-02-18 | Pfizer Products Inc. | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
| WO2008151434A1 (en) | 2007-06-12 | 2008-12-18 | The University Of British Columbia | Small cationic antimicrobial peptides |
| GB0714029D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
| GB0714030D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
| AU2008364202A1 (en) | 2008-11-24 | 2011-07-07 | Sentinella Pharmaceuticals, Inc. ("Sentinella") | Lantibiotic carboxyamide derivatives with enhanced antibacterial activity |
| GB0900599D0 (en) | 2009-01-14 | 2009-02-18 | Novacta Biosystems Ltd | Treatment |
| DK2387580T3 (da) | 2009-01-14 | 2014-10-13 | Novacta Biosystems Ltd | Deoxyactagardinderivater |
| EA020733B1 (ru) | 2009-02-04 | 2015-01-30 | Новакта Биосистемс Лимитед | Производные актагардина |
| GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
| MX2012008819A (es) * | 2010-02-02 | 2012-09-28 | Novacta Biosystems Ltd | Sales de lantibioticos. |
| CN103052383A (zh) | 2010-07-14 | 2013-04-17 | 诺瓦克塔生物系统有限公司 | 含有b型羊毛硫抗生素的制剂 |
-
2010
- 2010-08-11 GB GBGB1013513.5A patent/GB201013513D0/en not_active Ceased
-
2011
- 2011-08-09 CA CA2807206A patent/CA2807206A1/en not_active Abandoned
- 2011-08-09 EP EP11749878.2A patent/EP2603204A2/en not_active Withdrawn
- 2011-08-09 EA EA201291463A patent/EA024344B1/ru not_active IP Right Cessation
- 2011-08-09 JP JP2013523659A patent/JP5865374B2/ja not_active Expired - Fee Related
- 2011-08-09 MX MX2013001470A patent/MX2013001470A/es not_active Application Discontinuation
- 2011-08-09 WO PCT/GB2011/001191 patent/WO2012020219A2/en not_active Ceased
- 2011-08-09 US US13/816,063 patent/US9192569B2/en not_active Expired - Fee Related
- 2011-08-09 CN CN201180038723.5A patent/CN103108628B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103108628A (zh) | 2013-05-15 |
| CA2807206A1 (en) | 2012-02-16 |
| WO2012020219A3 (en) | 2012-04-05 |
| GB201013513D0 (en) | 2010-09-22 |
| EA024344B1 (ru) | 2016-09-30 |
| EA201291463A1 (ru) | 2013-07-30 |
| JP2013533304A (ja) | 2013-08-22 |
| JP5865374B2 (ja) | 2016-02-17 |
| CN103108628B (zh) | 2015-08-05 |
| WO2012020219A2 (en) | 2012-02-16 |
| US9192569B2 (en) | 2015-11-24 |
| US20130137630A1 (en) | 2013-05-30 |
| EP2603204A2 (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502778B1 (en) | Antibody formulation | |
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| TN2014000431A1 (en) | Antibody formulatoin | |
| NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
| MX2016005395A (es) | Formulacion estable de insulina glulisina. | |
| WO2012076670A3 (en) | Antibody formulation | |
| PH12015502441A1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
| EA201590161A1 (ru) | Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона | |
| PE20150190A1 (es) | Formulacion farmaceutica | |
| IN2014MN02213A (enExample) | ||
| MX2019010479A (es) | Formulacion de anticuerpo anti her2. | |
| JO3508B1 (ar) | جهاز طبي محتوي على تركيبة عجينة مشتملة على أريببرازول كمكون فعال وتركيبة عجينة مشتملة على أريببرازول كمكون فعال | |
| WO2014066468A8 (en) | Stable, low viscosity antibody formulation | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| MX2014009660A (es) | Formulacion de anticuerpo anti-selectina p. | |
| WO2012020219A3 (en) | Formulations for infusion of type b lantibiotics | |
| WO2014012042A8 (en) | Intralipid as a contrast agent to enhance subsurface blood flow imaging | |
| UA110935C2 (uk) | Препарат інсуліну пролонгованої дії | |
| HK1191660A (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
| TH147124A (th) | สูตรผสมของอินซูลินซึ่งออกฤทธิ์นาน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |